The trial is assessing the therapy for individuals with ischemic heart failure of minimised ejection fraction.

Bristol Myers Squibb today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III ...

After an earlier trial showed patients with elevated levels of a cardiac stress marker benefited from its cell therapy, the firm shifted focus to this subset.

The role of centrosomal tubulin glutamylation has remained elusive for decades. Here, a new tool enables precise ...